Regulatory Affairs

Canada-based legal and consulting practice advising regulated-industry clients on psychedelic access, controlled-substance pathways, constitutional/regulatory issues, and policy-facing market development.

Canadian business law firm with published advisory work on legal and regulatory frameworks for psychedelics companies, including public-market and disclosure implications under Canadian law.

Law firm providing psychedelic-sector legal counsel across DEA/FDA pathway navigation, transactional support, and healthcare-compliance risk management for clinics, facilitators, and research organizations.

Psychedelic and psilocybin-focused legal practice supporting operators and organizations with regulatory navigation, compliance strategy, and legal risk mitigation in emerging plant-medicine markets.

International regulatory affairs consultancy (UK/EU/US footprint) supporting life-science organizations across development to post-licensing, including dedicated analysis of psychedelic-drug regulatory pathways.

Brazil-based law firm with a leading IP and life-sciences practice, contributing legal and regulatory analysis on psychedelic medicines in Brazil and advising on IP-protection strategy in regulated sectors.

Toronto-based boutique law firm operating a dedicated psychedelic law practice, advising individuals and organizations on regulatory compliance, governance, contracts, and legal risk in Canada’s psychedelic sector.

National law firm with a dedicated psychedelics and emerging therapies legal practice supporting organizations operating in complex U.S. therapeutic, regulatory, and commercialization pathways.

IHPI, the Ibogaine Healthcare Policy Institute, is a U.S.-based 501(c)(3) nonprofit focused on policy infrastructure for regulated ibogaine care. Its stated audience includes healthcare decision-makers such as CMS, Medicaid leaders, commercial payers, regulators, and health system executives. The organization says it provides neutral, decision-grade resources on safety, payment, and implementation for ibogaine treatment. IHPI frames its role as building the legal and operational infrastructure needed for regulated ibogaine treatment in the United States, with an emphasis on veterans and people affected by PTSD and opioid use disorder. Its work includes regulatory pathways, safety and delivery standards, and payer system infrastructure such as reimbursement mechanics, coding roadmaps, budget impact logic, and coverage criteria. A published April 2026 explainer indicates it is actively interpreting federal psychedelic policy for downstream implementation, coverage, and delivery questions.

Canadian law firm with a dedicated cannabis-and-psychedelics regulatory practice advising on Section 56 pathways, Special Access Program matters, licensing compliance, and controlled-substance legal strategy.

UK law firm with a dedicated psychoactive medicines practice providing regulatory, commercial, and IP counsel for psychedelic and cannabis organizations across research, clinic, and supply-chain contexts.

Toronto law firm focused on psychedelics and controlled-substance legal operations, supporting licensing strategy, Health Canada interactions, audit/inspection readiness, and compliance architecture across research-to-commercial pathways.

Psychedelic-focused law firm advising clinics, researchers, nonprofit organizations, and religious groups on controlled-substance licensing, compliance strategy, and policy-facing legal frameworks.

Law firm focused on cannabis and psychedelics law, with advisory work spanning FDA/DEA pathways, controlled-substance compliance, and policy implementation in emerging psychedelic regulatory programs.